JEIL PHARMA HOLDINGS INC. (002620) AI Stock Analysis

JEIL PHARMA HOLDINGS INC.

(Korea Exchange:002620)

Select Model

Rating:51Neutral

Price Target:KRW 6,914.00▲(0.93% Upside)

Action:initiatedcoverage

Date:10/28/26

The score is held back primarily by weak cash-flow quality (negative free cash flow) and still-pressured core operating profitability despite improving top-line and gross margin. Technicals also point to a downtrend with bearish momentum. Valuation is relatively reasonable and provides some support, but it does not outweigh the operating and cash-flow risks.

Positive Factors

Improving Revenue and Gross MarginThe sharp TTM revenue improvement and higher gross margin indicate better commercial traction and product economics. If sustained, this combination can expand the earnings base and provide more resources for reinvestment, although operating-level profitability still needs to follow.

Negative Factors

Negative Free Cash FlowNegative free cash flow shows that the company is not yet consistently self-funding after investment needs. This can limit financial flexibility, increase reliance on external funding, and make reported earnings less useful as an indicator of durable cash-generating power.

JEIL PHARMA HOLDINGS INC. (002620) vs. SPDR S&P 500 ETF (SPY)

Market Cap: KRW 103.16B
Dividend Yield: 1.04%
Average Volume (3M): 4,518
Price to Earnings (P/E): 12.2
Beta (1Y): 0.09
Revenue Growth: -15.55%
EPS Growth: ―
Country: KR
Employees: 40
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

JEIL PHARMA HOLDINGS INC. Business Overview & Revenue Model

Company Description

Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API po...

JEIL PHARMA HOLDINGS INC. Financial Statement Overview

Summary

Mixed fundamentals. Income statement shows a return to profitability and strong TTM revenue growth with improving gross margin, but core operating profitability remains pressured (negative EBITDA margin and slightly negative EBIT). Balance sheet leverage is moderate (debt-to-equity ~0.59) with improving ROE, but cash flow is the key weakness: free cash flow remains negative and historical cash generation has been unstable.

Income Statement

54Neutral

Balance Sheet

67Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	622.49B	657.61B	779.82B	804.04B	792.96B	762.57B
Gross Profit	245.74B	226.27B	206.52B	214.58B	180.48B	180.51B
EBITDA	-39.21B	30.02B	-38.65B	9.25B	-67.00B	6.14B
Net Income	8.43B	14.64B	-51.16B	-16.25B	-83.15B	-12.87B
Balance Sheet
Total Assets	891.76B	876.04B	890.43B	880.00B	865.68B	892.42B
Cash, Cash Equivalents and Short-Term Investments	87.50B	79.31B	75.88B	59.13B	53.40B	47.22B
Total Debt	184.74B	167.37B	155.21B	214.14B	162.62B	115.07B
Total Liabilities	421.10B	407.55B	453.04B	477.81B	445.88B	392.11B
Stockholders Equity	314.47B	318.74B	306.95B	319.46B	337.76B	411.73B
Cash Flow
Free Cash Flow	-1.85B	-7.89B	-2.32B	-14.25B	-42.21B	-10.33B
Operating Cash Flow	11.86B	390.26M	4.54B	-4.42B	-20.80B	13.40B
Investing Cash Flow	-22.99B	-13.44B	2.27B	-13.43B	-17.56B	7.33B
Financing Cash Flow	16.31B	10.02B	14.22B	20.62B	44.91B	-12.24B

JEIL PHARMA HOLDINGS INC. Technical Analysis

Technical Analysis SentimentNegative

Last Price6850.00

Price Trends

50DMA7454.20Negative

100DMA7194.40Negative

200DMA7810.45Negative

Market Momentum

MACD-183.90Positive

RSI27.59Positive

STOCH20.01Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:002620, the sentiment is Negative. The current price of 6850.00 is below the 20-day moving average (MA) of 7287.50, below the 50-day MA of 7454.20, and below the 200-day MA of 7810.45, indicating a bearish trend. The MACD of -183.90 indicates Positive momentum. The RSI at 27.59 is Positive, neither overbought nor oversold. The STOCH value of 20.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:002620.

JEIL PHARMA HOLDINGS INC. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KR:002620 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KR:000020	58Neutral	KRW 141.36B	7.82	―	4.80%	6.59%	185.66%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
KR:271980	53Neutral	KRW 125.32B	7.07	―	―	-17.85%	81.91%
KR:002620	51Neutral	KRW 103.16B	12.22	―	1.04%	-15.55%	―
KR:003000	50Neutral	KRW 362.10B	63.51	―	3.41%	22.17%	-38.54%
KR:000520	47Neutral	KRW 164.86B	-4.34	―	―	-4.54%	-88.02%
KR:003520	40Underperform	KRW 170.27B	-27.53	―	―	0.60%	-6964.46%

* General Sector Average

Performance Comparison

KR:002620 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KR:002620	JEIL PHARMA HOLDINGS INC.	6720.00	-1121.77	-14.31%
KR:000020	Dong Wha Pharm Co., Ltd.	5100.00	-981.78	-16.14%
KR:000520	Samil Pharmaceutical Co., Ltd.	7650.00	-1560.00	-16.94%
KR:003000	Bukwang Pharmaceutical Co., Ltd.	3670.00	102.22	2.87%
KR:003520	YUNGJIN PHARM. CO. LTD	931.00	-1099.00	-54.14%
KR:271980	Jeil Pharmaceutical Co. Ltd.	8600.00	-5470.00	-38.88%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

JEIL PHARMA HOLDINGS INC. AI Stock Analysis